Skip to Content

Methenamine / sodium biphosphate Disease Interactions

There are 7 disease interactions with methenamine / sodium biphosphate:

Major

Laxatives (Includes methenamine/sodium biphosphate) ↔ inflammatory bowel disease

Severe Potential Hazard, Moderate plausibility. Applies to: Inflammatory Bowel Disease

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
Major

Laxatives (Includes methenamine/sodium biphosphate) ↔ intestinal obstruction disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  3. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
  5. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
View all 5 references
Major

Methenamine (Includes methenamine/sodium biphosphate) ↔ crystalluria

Severe Potential Hazard, High plausibility. Applies to: Renal Dysfunction, Dehydration

The use of methenamine salts (i.e. methenamine hippurate or mandelate), but not the base, is contraindicated in patients with severe renal impairment or dehydration. Methenamine is excreted by the kidney and concentrated in the urine. In patients with low urinary output, the salts can precipitate and cause crystalluria.

References

  1. "Product Information. Mandelamine (methenamine)." Parke-Davis, Morris Plains, NJ.
  2. Gleckman R, Alvarez S, Joubert D, Matthews S "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm 36 (1979): 1509-12
  3. Klinge E, Mannisto P, Mantyla R, Lamminsivu U, Ottoila P "Pharmacokinetics of methenamine in healthy volunteers." J Antimicrob Chemother 9 (1982): 209-16
  4. Australian Drug Evaluation Committee "Adverse effects of drugs commonly used in the treatment of urinary tract infection." Med J Aust 1 (1972): 435-8
  5. "Product Information. Hiprex (methenamine)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  6. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
View all 6 references
Major

Methenamine (Includes methenamine/sodium biphosphate) ↔ gout

Severe Potential Hazard, Moderate plausibility. Applies to: Gout

Methenamine mandelate (salts), should be avoided in patients with gout as it may precipitate urate crystals in their urine. A similar situation may arise in patients with a predisposition to the formation of uric acid stones.

Major

Methenamine (Includes methenamine/sodium biphosphate) ↔ liver disease

Severe Potential Hazard, High plausibility. Applies to: Liver Disease

The use of methenamine and its salts (i.e. methenamine hippurate or mandelate) is contraindicated in patients with severe hepatic impairment. Methenamine is hydrolyzed to ammonia and formaldehyde in the urine under acidic conditions. Patients with liver disease may already have elevated ammonia levels, which can cause or exacerbate hepatic encephalopathy. Methenamine hippurate has also been associated with isolated cases of transient elevations in serum transaminases. The manufacturer recommends periodic liver function tests during therapy, particularly in patients with preexisting liver dysfunction.

References

  1. Strom J, Jun H "Kinetics of hydrolysis of methenamine." Pharm Bull 23 (1975): 651
  2. "Product Information. Mandelamine (methenamine)." Parke-Davis, Morris Plains, NJ.
  3. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  4. Gleckman R, Alvarez S, Joubert D, Matthews S "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm 36 (1979): 1509-12
  5. "Product Information. Hiprex (methenamine)." Hoechst Marion-Roussel Inc, Kansas City, MO.
View all 5 references
Major

Phosphates (Includes methenamine/sodium biphosphate) ↔ hypocalcemia

Severe Potential Hazard, High plausibility. Applies to: Hypocalcemia, Pancreatitis

The use of phosphates is in general contraindicated in conditions where high potassium, high phosphate, or low calcium may be encountered such as hypoparathyroidism, osteomalacia, acute pancreatitis, or chronic renal disease.

References

  1. "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals, Tampa, FL.
  2. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
Major

Sodium phosphate (Includes methenamine/sodium biphosphate) ↔ electrolyte imbalance

Severe Potential Hazard, High plausibility. Applies to: Dehydration, Congestive Heart Failure, Phosphate Imbalance, Gastrointestinal Obstruction, Inflammatory Bowel Disease

The use of sodium phosphates is contraindicated in patients with congenital megacolon, intestinal obstruction, imperforate anus, active inflammatory disease or congestive heart failure. Serious, potentially life-threatening electrolyte imbalance such as hypocalcemia and hyperphosphatemia can result with prolonged or excessive use of phosphate laxatives. Hypernatremia and dehydration can occur due to improper dilution of hypertonic saline laxatives. Therapy with sodium phosphates should be administered cautiously and frequency of administration limited in patients with renal dysfunction, colostomy, cardiac dysfunction, or electrolyte imbalance. Clinical monitoring of electrolyte concentrations is recommended.

References

  1. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
  2. "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical, Abbott Park, IL.

Methenamine / sodium biphosphate drug interactions

There are 748 drug interactions with methenamine / sodium biphosphate

Methenamine / sodium biphosphate alcohol/food interactions

There is 1 alcohol/food interaction with methenamine / sodium biphosphate

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide